Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro

Biochemical Pharmacology

Volumn 50, Issue 8, 1995, Pages 1281-1286

  Begleiter, Asher ^a,b   K Leith, Marsha ^a,b  

^a Manitoba Cancer Treatment and Research Foundation   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

combination therapy; doxorubicin; DT diaphorase; EMT6 cells; mitomycin C; mouse marrow cells

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST TUMOR; CELL KILLING; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME INDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0028875458     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02014-4     Document Type: Article

References (45)

1. Daunorubicin and Adriamycin in cancer treatment: An analysis of the roles and limitations
2. Cardiotoxicity of adriamycin and related anthracyclines
3. The clinical evaluation of analogs. III. Anthracyclines
4. Anthracyclines
5. DNA topoisomerase II as the primary target of anti-tumor anthracyclines
6. Free radicals in anticancer drug pharmacology
7. The experimental development of bioreductive drugs and their role in cancer therapy
8. Cellular pharmacology of quinone bioreductive alkylating agents
9. Mitomycin: Its evolving role in the treatment of breast cancer
10. Mitomycin therapy in gastric cancer
11. Experience with mitomycin in the treatment of non-small cell lung cancer
12. The use of mitomycin in esophageal cancer
13. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma
14. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomized study
15. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result.
16. Studies related to antitumor antibiotics. Part V. Reaction of mitomycin C with DNA examined by ethidium fluoresence assay
17. DNA alkylation by enzyme-activated mitomycin C
18. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA
19. Free radical formation by antitumor quinones
20. Increased sensitivity of quinone resistant cells to mitomycin C
21. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C
22. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase
23. 5 reductase
24. DT-diaphorase and cancer chemotherapy
25. DT-diaphorase in activation and detoxification of quinones
26. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors
27. Role of NAD-(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia
28. Decreased NAD-PH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
29. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions
30. DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and Superoxide radical formation
31. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumor tissues
32. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis
33. The electrophile counterattack response: Protection against neoplasia and toxicity
34. Increase of NAD-(P)H:quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity
35. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol
36. Regulation of human NAD(P)H:quinone oxidoreductase gene: Role of AP1 binding site contained within human antioxidant response element
37. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Characterization of a DNA-protein interaction at the antioxidant responsive element and induction by 12-O-tetradecanoylphorbol 13-acetate
38. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues
39. Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells
40. Enzyme induction by daunorubicin in neonatal heart cells in culture
41. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: A screening assay for anticarcinogenic enzyme inducers
42. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2′-deoxycoformycin and deoxyadenosine in vitro
43. Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro
44. In vitro clonal assays for murine multipotential and lineage restricted myeloid progenitor cells